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Long non-coding RNAs (lncRNAs) are a novel class of reg-
ulatory genes that play critical roles in various processes
ranging from normal development to human diseases such
as cancer progression. Recent studies have shown that
lncRNAs regulate the gene expression by chromatin remodel-
ling, transcription, splicing and RNA decay control, enhancer
function, and epigenetic regulation. However, little is known
about translation regulation by lncRNAs. We identiﬁed a
translational regulatory lncRNA (treRNA) through genome-
wide computational analysis. We found that treRNA is
upregulated in paired clinical breast cancer primary and
lymph-node metastasis samples, and that its expression
stimulates tumour invasion in vitro and metastasis in vivo.
Interestingly, we found that treRNA downregulates the
expression of the epithelial marker E-cadherin by suppressing
the translation of its mRNA. We identiﬁed a novel ribonu-
cleoprotein (RNP) complex, consisting of RNA-binding pro-
teins (hnRNP K, FXR1, and FXR2), PUF60 and SF3B3, that is
required for this treRNA functions. Translational suppression
by treRNA is dependent on the 30UTR of the E-cadherin
mRNA. Taken together, our study indicates a novel mechan-
ism of gene regulation by lncRNAs in cancer progression.
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Introduction
RNAs have long been considered as an intermediate between
DNA sequences and proteins that execute cellular functions.
However, protein-coding genes represent only 2% of the human
genome. Recent genome-wide analyses suggest that there are at
least thousands of non-coding RNAs (ncRNAs) transcribed from
mammalian genomes (Orom et al, 2010; Cabili et al, 2011). There
are two major classes of ncRNAs, the small ncRNA, such as
microRNAs (miRNAs) and long ncRNAs (lncRNAs), which
consists of ncRNAs 4200 nucleotides. Although ribosome
proﬁling showed that lncRNAs are bound by ribosomes, the
large majority of lncRNAs are not translated into peptides or
proteins (Banfei et al, 2012; Guttman et al, 2013). Extensive
studies have shown that small ncRNAs have diverse biological
functions in development, physiological, and pathological
processes, and are critical regulators in human diseases such as
cancer progression (Calin and Croce, 2006; He et al, 2007; Bartel,
2009; Ebert and Sharp, 2010). Unlike the small ncRNAs, very
little is known about the expression and function of lncRNAs.
lncRNAs have been shown to be involved in cellular pro-
cesses such as apoptosis and cell cycle (Khalil et al, 2009;
Mattick, 2009; Gupta et al, 2010; Huarte et al, 2010; Kino et al,
2010; Poliseno et al, 2010; Cesana et al, 2011; Guttman et al,
2011) and development including differentiation, X chromo-
some inactivation, and genomic imprinting (Mancini-Dinardo
et al, 2006; Tian et al, 2010; Guttman et al, 2011). They have
also been implicated in human diseases such as coronary
artery disease, amyotrophic lateral sclerosis, and Alzheimer’s
disease (Faghihi et al, 2008; Wang et al, 2008; Harismendy
et al, 2011). In addition, lncRNAs have been shown to have
oncogenic and tumour suppression functions in cancer
development (Petrovics et al, 2004; Calin et al, 2007; Beltran
et al, 2008; Perez et al, 2008; Li et al, 2009; Mourtada-
Maarabouni et al, 2009; Benetatos et al, 2010; Gupta et al,
2010; Huarte et al, 2010). LncRNAs exert their regulatory
functions through a variety of mechanisms, including chromo-
some remodelling, splicing, and mRNA stability (Azzalin et al,
2007; Martianov et al, 2007; Rinn et al, 2007; Faghihi et al,
2008; Nagano et al, 2008; Wang et al, 2008; Mercer et al, 2009;
Ponting et al, 2009; Bernard et al, 2010; Kim et al, 2010; Liu
et al, 2010; Orom et al, 2010; Schmitz et al, 2010; Tian et al,
2010; Tripathi et al, 2010; Tsai et al, 2010; Yap et al, 2010; Flynn
et al, 2011; Gong and Maquat, 2011; Heo and Sung, 2011; Khalil
and Rinn, 2011; Kotake et al, 2011; Maison et al, 2011; Wang
and Chang, 2011; Wapinski and Chang, 2011). Although most
of the steps in gene expression can be regulated by lncRNAs,
little is known about translational regulation by lncRNAs.
Previously, we identiﬁed human translational regulatory
lncRNA (treRNA) (originally named as ncRNA-a7) through
genome-wide computational analysis, and showed that
treRNA can function as an enhancer and regulate Snail
transcription in cis (Orom et al, 2010). TreRNA consists of
two exons and its transcript is spliced and polyadenylated.
TreRNA contains three putative open reading frames (ORFs);
however, ribosome proﬁling experiment failed to detect
the treRNA association with ribosomes and the putative
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peptides encoded by treRNA were not detected by the
ENCODE proteomic study (Guo et al, 2010; Banfei, et al,
2012; Guttman et al, 2013). In addition, in vitro translation of
treRNA did not generate any detectable peptide (Orom et al,
2010). Thus, treRNA is considered as an lncRNA. Here, we
report the identiﬁcation of a novel RNA–protein complex that
mediates the metastasis-promoting function of treRNA by
translational regulation.
Results
treRNA is overexpressed in lymph-node metastatic
human breast cancer samples
To explore the relevance of treRNA in cancer, we examined the
treRNA expression in the matched primary and lymph-node
metastatic tumour specimen from the same patient by quanti-
tative RT–PCR (qRT–PCR). Expression analysis of treRNA in
12 primary breast-cancer carcinoma and the corresponding
lymph-node metastases pairs, each from the same patient,
showed markedly higher treRNA levels in the metastases of
all 12 pairs (Figure 1). The average levels of log-transformed
gene expression between lymph-node metastasis and primary
tumour were signiﬁcantly different (Po0.0001). The geometric
mean of the ratio of gene expression levels in metastasis versus
that in primary tumour is 3.72 (95% conﬁdence interval of
2.79–4.96), indicating a signiﬁcant association between the
expression level of treRNA and metastatic progression. We
also determined that the expression of treRNA expression
was signiﬁcantly higher in colon cancer specimens than in
healthy controls (Supplementary Figure S1). This suggested
that increased expression of treRNA may be a common feature
involved in tumour progression and metastasis.
treRNA promotes tumour invasion in vitro and
metastasis in vivo
Because treRNA is upregulated in metastatic clinical samples,
we examined the functional role of treRNA in tumour
invasion and metastasis. Enforced expression of treRNA in
non-invasive and non-metastatic human breast cancer
MCF7 cells signiﬁcantly increased cell migration and cell
invasion through Matrigel, whereas control lncRNA HAR1A
did not (Figure 2A and B). The enforced expression level of
treRNA in MCF7 cells was within the range of treRNA
expression in clinical samples (Supplementary Figure S2).
The expression of treRNA or HAR1A in MCF7 cells did not
affect cell proliferation in vitro (Supplementary Figure S3). To
determine its functions in vivo, luciferase-tagged MCF7 cells
(MCF7-luc) expressing treRNA or a vector control were trans-
planted into mouse mammary fat pads. The growth of pri-
mary tumours in MCF7-luc cells expressing treRNA is slightly
higher than MCF7-luc cells expressing a vector control
(Supplementary Figure S4), indicating that treRNA may affect
primary tumour growth. Lung metastasis developed
in mice following the transplantation of MCF-luc cells expres-
sing treRNA (Figure 2C), whereas no lung metastasis devel-
oped following the transplantation of MCF7-luc cells
expressing a vector control (Figure 2C). To determine the
functions of endogenous treRNA in migration, invasion, and
metastasis, we used two different small-interfering RNAs
(siRNAs) to knockdown the expression of treRNA in A549
cells (Supplementary Figure S5). Knockdown of treRNA
did not affect cell proliferation in vitro (Supplementary
Figure S6). Knockdown of treRNA in A549 cells dramatically
suppressed cell migration and invasion (Supplementary
Figure S7). To determine its function in vivo, luciferase-tagged
A549 cells (A549-luc) expressing treRNA siRNAs or a control
siRNA were transplanted into mice via tail vein injection.
Although there was no clear luciferase signals in the animals
transplanted with A549-luc cells expressing treRNA siRNAs
when the entire animals were imaged, imaging of the lungs
dissected from the animals showed that metastasis was
developed in these animals (Figure 2D). However, the lucifer-
ase signals of lung metastasis in A549-luc cells expressing
treRNA siRNAs were signiﬁcantly lower than cells expressing
a control siRNA (Figure 2D), demonstrating that knockdown
of endogenous treRNA suppressed metastasis in vivo. Taken
together, these results indicated that treRNA was capable of
promoting tumour invasion in vitro and metastasis in vivo.
treRNA suppresses epithelial markers
Because we have shown that treRNA downregulation de-
creases the expression of metastasis-promoting gene Snail
(Orom et al, 2010), it is possible that the effect of enforced
treRNA expression on invasion and metastasis is modulated
by Snail. To address this issue, we evaluated the impact of
enforced treRNA expression on Snail expression. To our
surprise, treRNA upregulation had no effect on Snail
expression (Supplementary Figure S8), which indicated that
treRNA is required but not sufﬁcient for Snail expression.
Thus, we concluded that the increase in invasion and metas-
tasis caused by enforced treRNA expression was not modu-
lated by changes in Snail expression. Because the loss of
epithelial markers is frequently associated with metastasis
(Steeg, 2006; Chang et al, 2008; Cook et al, 2011; Valastyan
and Weinberg, 2011), we assessed the effects of treRNA
expression on epithelial markers. Enforced expression of
treRNA in MCF7 cells signiﬁcantly suppressed E-cadherin
(Figure 3A), and to a lesser extent zonula occludens-1






















Figure 1 treRNA expression in clinical breast cancer specimens.
Each bar represents the percentage of GAPDH-normalized treRNA
expression in 12 pairs of primary breast cancer and lymph-node
metastasis samples (each pair came from the same patient). The
expression of treRNA in the primary breast cancer sample in each
pair was scaled to 100% to allow comparison. treRNA expression is
signiﬁcantly higher in the metastasis samples compared with the
primary samples (Po0.0001). The geometric mean of the ratio of
gene expression levels in the metastatic versus the primary tumour
is 3.72 (95% conﬁdence interval is 2.79–4.96).
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expression of ﬁbronectin and to a lesser extent vimentin
(Figure 3A). Thus, treRNA expression in MCF7 cells induced
a partial epithelial–mesenchymal transition phenotype with-
out affecting Snail expression. Conversely, knockdown of
treRNA in A549 cells increased the expression of
E-cadherin, ZO-1, and b-catenin and decreased the expres-
sion of vimentin and ﬁbronectin (Figure 3B). qRT–PCR was
performed to determine whether the suppression of epithelial
markers by treRNAwas a result of reduced mRNA expression,
reﬂecting an effect on transcription and/or stability of the
mRNA. qRT–PCR showed that there was no change in the
mRNA levels of E-cadherin, ZO-1, and b-catenin, indicating
that treRNA regulates the expression of epithelial markers
independent of changes in mRNA levels (Figure 3C;
Supplementary Figure S9). In addition, the lack of effect on
mRNA levels was consistent with a Snail-independent me-
chanism. We then determined the cellular location of spliced
treRNA. Nuclear and cytoplasm fractionation was isolated
from A549 cells, and the expression of endogenous treRNA
was quantiﬁed by qRT–PCR. Approximately 75% of spliced
treRNA was located in the cytoplasm (Supplementary
Figure S10).
TreRNA suppresses the translation of the E-Cadherin
mRNA
To determine whether treRNA suppressed the translation of
the E-cadherin mRNA, we used polysome analysis to evaluate
the translational status of E-cadherin mRNA in MCF7 cells
expressing treRNA or a vector control. Basically, polysome
analysis involves separating mRNA/protein complexes
through a 10–50% sucrose gradient, isolating RNA from the
fractions, and determining the distribution of E-cadherin
mRNA within the gradient. The distribution of an mRNA
within the gradient reﬂects its translational efﬁciency with
efﬁciently translated RNAs associated with high-molecular
weight (HMW, fractions 9–11) polysomes (heavy polysomes)
and with inefﬁciently translated mRNAs associated with low-
molecular weight (LMW, fractions 7–8) polysomes (light
polysomes) or in the non-polysomal portion of the gradient
(fractions 1–6). Polysome analysis showed that in MCF7 cells
expressing a vector control, over 80% of the E-cadherin
mRNA was associated with HMW polysomes (fractions
9–11), indicating efﬁcient translation (Figure 3D). In contrast,
enforced expression of treRNA resulted in the redistribution
of over 80% of the E-cadherin mRNA to the LMW and
























































































































Figure 2 treRNA promotes migration and invasion in vitro and metastasis in vivo. (A, B) Quantitative analysis of MCF7 cells expressing a
vector control, treRNA, or control long non-coding RNA HAR1A in migration (A) and invasion (B) assays. Data represent mean and s.d.
(triplicates). (C) Transplantation of MCF7 cells expressing luciferase and treRNA in mouse mammary fat pads led to lung metastasis.
Transplantation of MCF7 cells expressing a vector control does not lead to metastasis. (D) Knockdown of endogenous treRNA suppressed lung
metastasis in vivo. A549 cells expressing luciferase and two different treRNA siRNAs or a control siRNA were transplanted into mice via tail
vein injection. Lung metastasis was signiﬁcantly reduced in A549 cells with treRNA knockdown. The data were collected from three
independent experiments and presented as mean±s.d.
LncRNAs translationally regulate metastasis
K Gumireddy et al
2674 The EMBO Journal VOL 32 | NO 20 | 2013 &2013 European Molecular Biology Organization
non-polysomal portion of the gradient (Figure 3D). This effect
on E-cadherin did not appear to be a general phenomenon as
the distribution of the GAPDH mRNA was unaffected with
over 80% of this mRNA associated with HMW polysomes in
both cases (Figure 3D). Together, these data indicated that
treRNA altered the polysomal distribution of the E-cadherin
mRNA without affecting global translation.
Identiﬁcation of treRNA ribonucleoprotein complex(s)
that mediates treRNA function
To elucidate the molecular mechanisms of translation sup-
pression by treRNA, we utilized an afﬁnity puriﬁcation
method by tagging treRNA with an MS2 RNA at its 30 end
to isolate protein complex(es) that bind to treRNA and
mediate its functions (Supplementary Figure S11). This tagged
treRNA had the same translational suppression function as an
untagged treRNA (Supplementary Figure S12). We generated
an afﬁnity matrix by expressing a fusion protein of bacter-
iophage MS2 binding protein and maltose binding protein
(MBP) that was bound to amylose beads. Cytoplasmic ex-
tracts were isolated from the MCF7 cells expressing MS2-
tagged treRNA or MS2 tag control and applied to the afﬁnity
matrix. Proteins binding to the afﬁnity matrix were then
isolated and subjected to mass spectrometry analysis. We
selected proteins that have had a higher number of spectral


























































































































Figure 3 treRNA suppresses the expression of epithelial markers at the translation step. (A) Immunoblots of epithelial and mesenchymal
markers in MCF7 cells expressing treRNA or a vector control or a control long non-coding RNA HAR1A. MCF7 cells expressing treRNA showed
the inhibition of the expression of epithelial markers E-cadherin, ZO-1, and b-catenin; and the increase in the expression of mesenchymal
markers ﬁbronectin and vimentin. (B) Immunoblots of epithelial and mesenchymal markers in A549 cells that express treRNA endogenously.
A549 cells expressing two different treRNA siRNAs showed the increase in the expression of epithelial markers E-cadherin, ZO-1, and
b-catenin. (C) Quantitative RT–PCR in MCF7 cells expressing treRNA and MCF7 cells expressing a vector control showed no difference in the
RNA expression of epithelial markers E-cadherin, ZO-1, and b-catenin. Experiment was carried out in triplicate. Data were presented as
mean±s.d. (D) Polysome proﬁles of MCF7 cells expressing treRNA or a vector control. The polysomal distribution of the E-cadherin and
GAPDH mRNAs was determined by isolating the RNA from each fraction collected from a 10–50% sucrose gradient. The arrow indicates the
location of the 80S ribosome. The amount of the E-cadherin and GAPDH mRNAs was determined by qRT–PCR. The percentage of the mRNA
level in each fraction from MCF7 cells expressing treRNA or a vector control is shown. Experiment was carried out in triplicate. Data were
represented as mean±s.d. Source data for this ﬁgure is available on the online supplementary information page.
LncRNAs translationally regulate metastasis
K Gumireddy et al
2675&2013 European Molecular Biology Organization The EMBO Journal VOL 32 | NO 20 | 2013
based on the fold increase in spectral counts of tagged treRNA
versus MS2 tag alone (Figure 4A). There were three RNA-
binding proteins among the top hits from the analysis, hnRNP
K, FXR1, and FXR2. hnRNP K shares similar structure with
other poly(c)-binding proteins (PCBPs) such as hnRNP E1
and hnRNP E2. It is expressed in both the cytoplasm and the
nucleus, and is involved in multiple steps of gene expression,
such as chromatin remodelling, transcription, splicing, mRNA
stability, and translation (Tomonaga and Levens, 1995;
Ostareck et al, 1997; Ostareck-Lederer et al, 1998; Kim et al,
2000; Shnyreva et al, 2000; Evdokimova et al, 2001; Ostareck-
Lederer et al, 2002; Ostrowski et al, 2003; Bomsztyk et al,
2004; Eiring et al, 2010; Hussey et al, 2011). FXR1 and FXR2
belong to a family of RNA-binding proteins, which also
includes FMR1, the absence of which is the major cause of
the Fragile X syndrome (Jin and Warren, 2000; Hoogeveen
et al, 2002). These proteins play critical roles in development
(Hoogeveen et al, 2002). FXR1, FXR2, and FMR1 can interact
with each other and with themselves (Ceman et al, 1999).
Although they can shuttle between cytoplasm and nucleus,
their main localization in cells is the cytoplasm where they
associate with ribosomes and form ribonucleoprotein (RNP)
complexes (Hoogeveen et al, 2002). hnRNP K, FXR1, and
FXR2 all contain RNA-binding KH domains, which are


















∞ indicates the protein










































































































































































































































































































































































































































Figure 4 Identiﬁcation of proteins associated with treRNA. (A) Top protein candidates from mass spectrometry analysis are listed. The fold
ratios of spectral counts of protein candidates in cells expressing MS2-tagged treRNA or MS2 tag control vector were calculated.N indicates
that these proteins were detected only in cells expressing treRNA, but not in cells expressing a vector control. (B–E) The components of treRNA
RNP complex are required for treRNA functions. (B) The effects on E-cadherin expression in MCF7 cells expressing treRNA by the knockdown
of the protein candidates frommass spectrometry analysis. Knockdown of hnRNP K, FXR1, FXR2, and PUF60 expression by two different short-
hairpin RNAs (shRNAs) in MCF7-treRNA cells rescued the suppression of E-cadherin by treRNA. (C) The effects on E-cadherin expression in
MCF7 cells by the knockdown of the protein candidates. Knockdown of hnRNP K, FXR1, FXR 2, BUB3, TRIM25 and hnRNP E1 expression
individually in MCF7 cells does not affect E-cadherin expression. Knockdown of PUF60 expression partially affects E-cadherin expression.
Knockdown of SF3B3 expression signiﬁcantly decreases E-cadherin expression, suggesting that SF3B3 is required for E-cadherin expression in
MCF7 cells. (D) MCF7-luc-treRNA cells expressing shRNAs targeting hnRNP K, FXR1, and FXR2 individually or in combination were
transplanted into mouse mammary fat pads. The number of mice that developed lung metastasis was reduced when hnRNP K or FXR2
expression was knocked down. No lung metastasis was developed when both hnRNP K and FXR2 expressions were knocked down, or hnRNP
K, FXR1, and FXR2 triple expression knockdown. (E) Lung metastatic tumour signals were measured using a luminescence Xenogen imaging
system. In the mice that developed lung metastases, tumour signals in the lung were signiﬁcantly reduced when hnRNP K or FXR2 expression
was knocked down when compared with that of cells expressing a control shRNA. There is no lung metastasis signal when both hnRNP K and
FXR2 expressions were knocked down, or in the hnRNP K, FXR1 and FXR2 triple expression knockdown. The graph showed the mean photon
ﬂux ±s.d. of three independent experiments. Source data for this ﬁgure is available on the online supplementary information page.
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important for their functions (Valverde et al, 2008) and all
have been shown to play a critical role in post-transcriptional
gene regulation (Vasudevan and Steitz, 2007; Glisovic et al,
2008; van Kouwenhove et al, 2011). We also selected two
other proteins for validation, RNP-binding protein PUF60 and
SF3B3, which is a subunit of splicing factor 3b protein
complex that has been shown to interact with PUF60
(Kielkopf et al, 2004; Corsini et al, 2009; Prigge et al, 2009).
PUF homologue has also been shown to attenuate translation
in C. elegans (Friend et al, 2012).
We next examined the effect of these proteins on
E-cadherin expression. The expression of treRNA does not
alter the expression of hnRNP K, FXR1, FXR2, PUF60,
and SF3B3 in MCF7 cells (Supplementary Figure S13). We
used two different short-hairpin RNAs (shRNAs) to knock-
down the expression of each of the ﬁve genes we selected
(Supplementary Figure S14). Knockdown of hnRNP K, FXR1,
and FXR2 expression in MCF7 cells expressing treRNA res-
cued the suppressed E-cadherin phenotype (Figure 4B).
Knockdown of PUF60 expression partially rescued the
E-cadherin suppression, whereas SF3B3 expression knock-
down did not rescue E-cadherin suppression (Figure 4B). We
also tested two other genes that rank high on the list, BUB3
and TRIM25, along with hnRNP E1, an RNA-binding protein
that shares similar structure with hnRNP K. Knockdown of
BUB33, TRIM25, or hnRNP E1 did not rescue the E-cadherin
suppression by treRNA (Figure 4B). To further determine
their effects on E-cadherin expression, we knocked down
the expression of these genes in MCF7 cells expressing a
vector control. Knockdown of hnRNP K or FXR1 or FXR2 or
BUB3 or TRIM25 or hnRNP E1 expression did not affect
E-cadherin expression, whereas PUF60 is partially required
and SF3B3 is required for E-cadherin expression (Figure 4C).
Although SF3B3 was not proven to mediate the suppression
by treRNA because it was required for E-cadherin expression,
it was important for treRNA function because it interacted
with PUF60 and treRNA complex. These results suggested
that the hnRNP K, FXR1, FXR2 and PUF60 mediated treRNA
effect on E-cadherin suppression, whereas SF3B3 appeared to
be required for E-cadherin expression.
We then determined whether hnRNP K, FXR1, and FXR2
were required for metastasis-promoting functions of treRNA
in vivo. We knocked down the expression of these three genes
individually or in combination in luciferase-tagged MCF7 cells
expressing treRNA and transplanted these cells into mouse
mammary fat pads. Knockdown of FXR1 or FXR2 expression
did not signiﬁcantly affect cell proliferation in vitro
(Supplementary Figure S15). Knockdown of FXR2 in MCF7
cells expressing treRNA did not affect primary tumour growth
in vivo (Supplementary Figure S16). Knockdown of hnRNP K
or FXR1 increased primary tumour growth, whereas double
knockdown of hnRNP K and FXR2 or triple knockdown of
hnRNP K, FXR1, and FXR2 signiﬁcantly decreased primary
tumour growth (Supplementary Figure S16), indicating that
the combination of hnRNP K and FXR2 expression was
required for primary tumour growth in vivo. Both metastasis
growth in lungs and the number of mice that developed
metastasis nodules were similar in mice transplanted with
MCF7-treRNA cells expressing FXR1 shRNA or a control
shRNA (Figure 4D and E). In contrast, both metastasis growth
in lungs and the number of mice that developed lung metas-
tasis were signiﬁcantly reduced in mice injected with MCF7-
treRNA cells expressing hnRNP K shRNA or FXR2 shRNA
when compared with cells expressing a control shRNA
(Figure 4D and E). Double knockdown of hnRNP K and
FXR2 or triple knockdown of hnRNP K, FXR2, and FXR1 in
MCF7-treRNA cells completely abolished the metastasis-pro-
moting function of treRNA in vivo (Figure 4D and E). These
results demonstrated that hnRNP K and FXR2 were required
for the treRNA function on metastasis in vivo.
TreRNA protein complex suppresses translation by
binding translation initiation factor EIF4G1
We performed RNA pull-down to determine whether treRNA
and hnRNP K, FXR1, FXR2, PUF60, and SF3B3 form a
ribonucleoprotein complex. Cytoplasmic MCF7 cell extracts
were incubated with in vitro-transcribed biotinylated tran-
scripts of treRNA or antisense treRNA (negative control), and
the presence of these proteins was detected by western
blotting. Pull-down with treRNA, but not with an antisense
treRNA, was able to detect all ﬁve proteins but not control
RNA-binding protein hnRNP E1 (Figure 5A), demonstrating
that all ﬁve proteins associate with treRNA. Because
treRNA suppressed translation and translation initiation
factor eIF4G1 was present in mass spectrometry analysis of
treRNA afﬁnity column pull-down (Figure 4A), we hypo-
thesized that eIF4G was associated with the treRNA–protein
complex. RNA IP indicated that treRNA was associated with
eIF4G1 in the complex (Figure 5A). To investigate whether
treRNA expression promoted RNP complex formation and the
binding of eIF4G1 to the complex, we immunoprecipitated
SF3B3 or eIF4G1 in MCF7 cells expressing treRNA or a vector
control or a control lncRNA HAR1A. Co-immunoprecipitation
experiments showed that SF3B3 was associated with PUF60
in MCF7 cells expressing treRNA or a vector control or
HAR1A (Figure 5B), conﬁrming the results from previous
publications that splicing factor 3B protein complex binds to
PUF60 (Corsini et al, 2009; Prigge et al, 2009). Interestingly,
SF3B3 interacted with hnRNP K, FXR1, FXR2, and eIF4G1
in MCF7 cells expressing treRNA, but not in MCF7 cells
expressing a vector control or HAR1A, demonstrating that
treRNA was required for the formation of treRNA RNP
complex and its binding to eIF4G1 (Figure 5B). Immuno-
precipitation (IP) of eIF4G1 further conﬁrmed the observation
that treRNA promoted treRNA–protein complex formation
and its binding to eIF4G1 (Figure 5C). To further validate
these results, we performed the converse experiments
with treRNA siRNAs to knockdown treRNA expression in
A549 cells that express endogenous treRNA. Co-immuno-
precipitation of SF3B3 or eIF4G1 in A549 cells transfected
with treRNA siRNAs or a control siRNA conﬁrmed that SF3B3
associated with PUF60 regardless of treRNA expression
(Figure 5D). Knockdown of endogenous treRNA expression
abolished the association of SF3B3 with the treRNA RNP
complex, hnRNP K, FXR1, FXR2, and its binding to eIF4G1
(Figure 5D and E). In order to further validate that endo-
genous treRNA interacted with treRNA RNP complex, we
performed UV cross-linking IP. A549 cells were UV cross-
linked and immunoprecipitated using an IgG control or
antibodies of FXR1 and FXR2, members of the treRNA RNP
complex. Quantitative real-time PCR analysis indicated that
treRNA was associated with FXR1 and FXR2 endogenously
(Figure 5F). In addition, when biotinylated treRNA was
incubated with MCF7 cytosolic cell extracts, the E-cadherin
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mRNA was present in the pull-down (Supplementary
Figure S17), indicating their association. Together, these
results suggested that treRNA expression promoted the bind-
ing of PUF60–SF3B3 complex to hnRNP K, FXR1, and FXR2 to
form a treRNA RNP complex and its’ binding to eIF4G1
affected translation.
Translation suppression by treRNA RNP complex is
dependent on the 3 0UTR of its target genes
It has been shown that RNA-binding proteins associate with
UTR regions of genes (Chaudhury et al, 2010; Kedde et al,
2010; Hussey et al, 2011). To identify the regions of the
E-cadherin mRNA that were required for the treRNA-
mediated translational suppression, we constructed reporter
plasmids by cloning the 30UTR of E-cadherin downstream of a
luciferase gene and its 50UTR upstream of a luciferase gene.
As ZO-1 and b-catenin expression levels were suppressed
by treRNA, we also analysed the UTRs of these mRNAs.
Enforced expression of treRNA in MCF7 cells or knockdown
of endogenous treRNA in A549 cells did not affect luciferase
activity when 50UTR reporter plasmids were transfected into
these cells. This indicated that the translation suppression by
treRNA was not dependent on the 50UTRs of target genes
(Figure 6A and B). Interestingly, treRNA expression in MCF7
cells signiﬁcantly decreased the luciferase signal of the 30UTR
reporter plasmid, and conversely knockdown of treRNA in
A549 cells considerably increased the luciferase activity
when 30UTR reporter plasmids were transfected (Figure 6C
and D). Together, these data indicated that elements in the
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Figure 5 TreRNA RNP complex binds to the translation initiation factor eIF4G1. (A) RNA pull-down was performed by incubating cytoplasmic
extracts of MCF7 cells with biotinylated treRNA or antisense treRNA (negative control) followed by detection of the presence of the treRNA
RNP complex by western blotting. All the treRNA RNP complex components, hnRNP K, FXR1, FXR2, PUF60, and SF3B3 were detected in
treRNA pull-down, but not in treRNA antisense pull-down. Translation initiation factor eIF4G1 was also detected in the treRNA pull-down,
demonstrating that it binds to treRNA RNP complex. RNA-binding protein hnRNP E1 that shares similar structure with hnRNP K was not
detected in treRNA pull-down. (B, C) SF3B3 or eIF4G1 was immunoprecipitated in MCF7 cells expressing treRNA or a vector control or control
long non-coding RNA HAR1A, and the proteins in the treRNA RNP complex were detected by western blotting. SF3B3 binds to PUF60 in
the absence or presence of treRNA. Upon treRNA expression, SF3B3 and PUF60 bind to hnRNP K, FXR1, FXR2, and eIF4G1. eIF4G1
immunoprecipitation further conﬁrmed the interaction of these proteins in the presence of treRNA. (D, E) SF3B3 or eIF4G1 was
immunoprecipitated in A549 cells that endogenously express treRNA and was transfected with treRNA siRNAs. Knockdown of treRNA
disrupts the binding of SF3B3 to hnRNP K, FXR1, FXR2, and eIF4G1, but not binding to PUF60. Immunoprecipitation of eIF4G1 further
conﬁrmed that the interaction of eIF4G1 with hnRNP K, FXR1, FXR2, PUF60, and SF3B3 requires treRNA expression. (F) Endogenous treRNA
was associated with FXR1 and FXR2. A549 cells were UV cross-linked or without UV cross-linking, and immunoprecipitated using an IgG
control or antibodies against FXR1 and FXR2. RNAs were extracted from the immunoprecipitation and quantitative RT–PCR indicated that
treRNA was associated with FXR1 and FXR2 endogenously. The data were collected from three independent experiments and presented as
mean±s.d. Source data for this ﬁgure is available on the online supplementary information page.
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suppression mediated by treRNA. In order to delineate the
sequences in the E-cadherin 30UTR that mediate this effect,
we used catRAPID computational program (Bellucci et al,
2011) to identify potential binding sites of hnRNPK, FXR1,
and FXR2 and found three regions (site 1: 12–80, site 2: 946–
1019; site 3: 1325–1396) each of which is predicted to contain
potential binding sites for all three proteins. We constructed
mutant reporter plasmids with the replacement of site 1,
site 2, or site 3 with their respective reverse sequences
(Figure 6E). Site 2 mutant partially rescued the suppression
of luciferase activity by treRNA (Figure 6E), whereas site 1 or
3 mutants had no effect (Figure 6E), indicating that site 2 of
the E-cadherin 30UTR was critical for treRNA complex func-
tions. These results suggested that translation suppression by
treRNA RNP complex was dependent on the 30UTRs of its
target genes.
Discussion
Our previous study demonstrated that treRNA controls gene
expression by enhancing the expression of neighbouring genes
in the nucleus (Orom et al, 2010). The present study indicated
that treRNA reduces the level of E-cadherin protein without
affecting the level of its mRNA. In addition, we showed that
the expression of treRNA results in the redistribution of the
E-cadherin mRNA from HMW polysomes to LMW polysomes.
Together, these data strongly indicate that treRNA suppresses
the translation of the E-cadherin mRNA. Thus, treRNA
employs different molecular mechanisms of gene regulation
in the nucleus and the cytoplasm. It has been suggested that
lncRNAs use various molecular machineries to regulate gene
expression (Azzalin et al, 2007; Martianov et al, 2007; Rinn
et al, 2007; Faghihi et al, 2008; Nagano et al, 2008; Wang et al,
2008; Bernard et al, 2010; Kim et al, 2010; Liu et al, 2010;
Orom et al, 2010; Schmitz et al, 2010; Tian et al, 2010; Tripathi
et al, 2010; Tsai et al, 2010; Yap et al, 2010; Flynn et al, 2011;
Gong and Maquat, 2011; Heo and Sung, 2011; Kotake et al,
2011; Maison et al, 2011; Wang and Chang, 2011; Yoon et al,
2012). Our results indicated that even one lncRNA, treRNA,
can use different mechanisms at multiple steps during the
transcription and translation cycles.
Our results showed that treRNA RNP complex mediates the
translational suppression of E-cadherin by treRNA. The exact
mechanism by which treRNA affects E-cadherin translation is
unknown, but it is important to note that it is likely not due to
direct hybridization of the target mRNA. Although we found
that the 30UTR of E-cadherin is required for the translational
suppression by treRNA, there is no sequence homology
between the sequences of treRNA and the 30UTR of
E-cadherin. Thus, unlike LincRNA-p21, which suppresses
translation through direct binding to its target mRNA (Yoon
et al, 2012), it is unlikely that direct hybridization between
treRNA and E-cadherin is responsible for this regulation.

























































































































Figure 6 Translational suppression by treRNA RNP complex is dependent on the 30UTRs of its target genes, but not on the 50UTRs. Reporter
plasmids were constructed by cloning the 30UTRs or 50UTRs of E-cadherin, ZO-1, b-catenin downstream or upstream of a luciferase gene. These
reporter plasmids were co-transfected with treRNA or a vector control, and Renilla luciferase (pRL-TK) (normalizing control) into MCF7 cells.
The reporter plasmids were also co-transfected with treRNA siRNAs or a control siRNA, and Renilla luciferase (pRL-TK) (normalizing control)
into A549 cells. Fireﬂy luciferase activity was normalized against the Renilla luciferase activity. Experiment was carried out in triplicate. Data
were presented as the mean±s.d. (A) There is no signiﬁcant change in luciferase signal of 50UTR reporter plasmids when treRNA expression is
upregulated in MCF7 cells or (B) knocked down in A549 cells, indicating that 50UTR is not required for treRNA functions. (C) The luciferase
activity of the 30UTR reporter plasmids was signiﬁcantly decreased in MCF7 expressing treRNA. (D) Conversely, the luciferase activity of the
30UTR reporter plasmids increased when treRNA is knocked down in A549 cells. (E) The 30UTR of E-cadherin (wt) was cloned downstream of a
luciferase gene to generate a reporter construct. The mutant reporter plasmids were generated by replacing the respective binding sites with
their respective reverse sequences in the 30UTR. MCF7 cells were transfected with the reporter constructs, a Renilla luciferase construct
(normalizing control), and treRNA (or a vector control). Luciferase activity was then determined. The site 2 mutant in the 30UTR of E-cadherin
partially rescued the suppression of luciferase activity by treRNA.
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the E-cadherin mRNA for hnRNP K, FXR1, and FXR2. These
proteins are part of the treRNA protein complex and it
may be through interactions with these binding proteins
that treRNA elicits its effects. As our knockdown data
indicate that hnRNP K, FXR1, and FXR2 do not directly
affect E-cadherin expression (Figure 4C), it is unlikely that
treRNA regulates the E-cadherin expression by competing for
these RNA-binding proteins. Further studies are required to
conﬁrm a direct model where treRNA protein complex acts
directly on E-cadherin mRNA. E-cadherin expression is regu-
lated by multiple cellular pathways. Its regulation by treRNA
is one of the mechanisms that control its expression. As the
treRNA RNP complex components are expressed in most cell
types, it is possible that the mechanism we have identiﬁed is
shared by other lncRNAs to regulate translation. Such a
translational regulation by lncRNAs provides another layer
of complexity in gene regulation beyond that described for
miRNA-mediated silencing of gene expression (Sonenberg
and Dever, 2003; Gebauer and Hentze, 2004; Filipowicz
et al, 2008; Sonenberg and Hinnebusch, 2009; Jackson
et al, 2010; Silvera et al, 2010; Fukaya and Tomari, 2012;
Meijer et al, 2013).
On the basis of the data from our study, we propose the
following model for the molecular mechanism of translation
suppression by treRNA. TreRNA promotes the formation of a
treRNA-associated protein (treRNP) complex consisting of
hnRNP K, FXR1, FXR2, PUF60, and SF3B3. This treRNP
complex interacts, directly or indirectly, with the 30UTR of
E-cadherin mRNA, and reduces the translation efﬁciency.
Further studies are required to evaluate this model and to
elucidate the precise mechanism in which the treRNA reg-
ulates the translation of E-cadherin mRNA.
In addition to the epithelial markers regulated by treRNA,
hnRNP K, FXR1, and FXR2 bind other mRNAs which are
potential targets of treRNA regulation. Whether other genes
regulated by treRNA RNP complex play a role in tumour
invasion and metastasis remains to be investigated.
Identiﬁcation of these genes regulated by treRNA will reveal
additional treRNA functions and the cellular processes that
are regulated by treRNA.
TreRNA is upregulated in clinical metastatic breast cancer
samples and primary colon cancer samples, suggesting that
treRNA is involved in cancer development including metas-
tasis. It is possible that cellular context is also important for
gene regulation by treRNA and other lncRNAs. Identiﬁcation
of lncRNAs involved in cancer progression will further im-
prove our understanding of aberrant gene regulations opera-
tive in cancer. It will also be interesting to investigate whether
lncRNAs and RNA-binding proteins can serve as potential
diagnostic and prognostic markers as well as therapeutic
targets in cancer. Elucidation of the functions of lncRNAs
and RNA-binding proteins with which they associate will
further improve our understanding of their roles in biological
processes and human diseases.
Materials and methods
Lentivirus transfection and transduction
To generate MCF7 cells stably overexpressing treRNA, human
treRNA was ampliﬁed by PCR using cDNA from A549 cells as a
template and cloned into lentiviral vector pLu. Lentivirus was
produced by co-transfecting subconﬂuent human embryonic kidney
(HEK) 293T cells with treRNA expression plasmid and packaging
plasmids pMDLg/pRRE and RSV-Rev) using Lipofectamine 2000.
Infectious lentiviruses were collected 48h after transfection, cen-
trifuged to remove cell debris, and ﬁltered through 0.45mm ﬁlters
(Millipore). MCF7 cells were transduced with the treRNA lentivirus.
Efﬁciency of overexpression was determined by real-time PCR.
MCF7 or MCF-treRNA cells stably expressing FXR1 shRNA,
FXR2 shRNA, hnRNP K shRNA, SF3B3 shRNA, PUF60 shRNA,
TRIM25 shRNA, BUB3 shRNA, hNRNPE1 shRNA, or control non-
target shRNA were established using a vector-based shRNA techni-
que. All shRNAs were cloned into pLKO lentiviral vector and
purchased from Sigma. The lentiviruses were processed as de-
scribed above and transduced into respective cells. The knockdown
efﬁciency was determined by western blotting.
treRNA knockdown
To knockdown treRNA expression, siRNA oligos (siRNA1: sense
50-GAAGGGAACCAGUGCUAAAUU-30, antisense 50-UUUAGCACUG
GUUCCCUUCUU-30; siRNA2: sense 50-CCGAUUUGAGAGAGUGAG
AUU-30, antisense 50-CUCACUCUCUCAAAUCGGUU-30) were used.
A control siRNA (sense: 50-GCUUCCUGCUACACAGAAUUU-30,
antisense 50-UUCUGUGUAGCAGGAAGCUU) was used as a negative
control. siRNAs were purchased from Dharmacon. A549 cells
were transfected with 100nM of siRNAs using Lipofectamine
RNAiMAX reagent (Invitrogen) following the manufacturer’s
instructions. Cells were collected after 48 h of transfection
for western blot analysis and RNA isolation. Knockdown was
conﬁrmed by qRT–PCR.
Tumour transplantation in mice
The MCF7 human breast cancer cell line stably expressing Fireﬂy
Luciferase gene with treRNA or respective shRNAs were routinely
maintained at 37 1C in a humidiﬁed atmosphere of 5% CO2 and
95% air in DMEM supplemented with 10% fetal bovine serum
(FBS). For orthotopic injections, 7106 cells/mouse were trans-
planted into the mammary fat pad of the female NOD/SCID mice
(6–8 weeks old). A slow-release pellet of 17b-estradiol (1.7mg,
90-day release; Innovative Research of America, Sarasota, FL) was
implanted subcutaneously in the dorsal interscapular region before
the transplantation of MCF7 cells. A549 cells stably expressing
Fireﬂy Luciferase gene were transfected with treRNA siRNAs
or a control siRNA. In all, 0.5106 cells/mouse were injected into
the lateral tail veins of 6- to 8-week-old NOD/SCID mice. Mice
bearing luciferase-positive tumours were imaged by an IVIS 200
Imaging system (Xenogen Corporation, Hopkinton, MA, USA).
Bioluminescent ﬂux (photons/s/sr/cm2) was determined for the
primary tumours or lung metastasis. Animal experiment protocols
were approved by the Institutional Animal Care and Use Committee
(IACUC) of the Wistar Institute. Animal procedures were conducted
in compliance with the IACUC.
Transwell migration and invasion assay
In vitro cell migration assays were performed as described pre-
viously (Gumireddy et al, 2009) using Trans-well chambers (8mM
pore size; Costar). Cells were allowed to grow to subconﬂuency
(B75–80%) and were serum starved for 24 h. After detachment
with trypsin, cells were washed with PBS, resuspended in serum-
free medium, and 250 ml of cell suspensions (2105 cells ml 1) was
added to the upper chamber. Complete medium was added to the
bottom wells of the chambers. The cells that had not migrated were
removed from the upper face of the ﬁlters using cotton swabs, and
the cells that had migrated to the lower face of the ﬁlters were ﬁxed
with 5% glutaraldehyde solution and stained with 0.5% solution of
Toluidine Blue in 2% sodium carbonate. Images of three random
 10 ﬁelds were captured from each membrane and the number of
migratory cells was counted. The mean of triplicate assays for each
experimental condition was used. Similar inserts coated with
Matrigel were used to determine the invasive potential in the
invasion assay.
Cell proliferation assay
To measure the proliferative activity of cells, each group of cells was
seeded in 96-well plates at a density of 4103 cells per well in
triplicate. Cell proliferation was quantiﬁed at day 0, day 1, day 2,
and day 3 with a CellTiter 96 AQeous Non-radioactive Cell
Proliferation Assay system (Promega, Madison, WI, USA) according
to the manufacturer’s protocol. Brieﬂy, cells were incubated with
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20ml of MTS/PMS solution for 4 h at 37 1C in a humidiﬁed 5% CO2
atmosphere. Cell proliferation was then measured at 490nm using a
multi-well plate reader (Wallac Victor, PerkinElmer). Cell growth
curves were plotted with OD value versus time. Three independent
experiments were performed.
RNA isolation, reverse transcription, and real-time PCR
analysis
Total RNA was extracted from cell lines, frozen primary and
metastasis tissues using Trizol total RNA isolation reagent
(Invitrogen), according to the manufacturer’s speciﬁcations and
treated with Turbo DNase (Ambion). cDNA was synthesized from
total RNA using random hexamers with a TaqMan cDNA Reverse
Transcription Kit (Applied Biosystems). Gene primers were de-
signed using a Primer Express v3.0 Software and real-time PCR
was performed using the SYBR Green Jumpstart Taq ReadyMix
(Sigma). Levels of E-cadherin (Assay ID: Hs01023894) and GAPDH
(Assay ID: Hs99999905) mRNAs were ampliﬁed using TaqMan Gene
Expression Assays (Applied Biosystems). All reactions were carried
out on the 7500 Fast Real Time PCR system (Applied Biosystems).
The average of three independent analyses for each gene and sample
was calculated using the DD threshold cycle (Ct) method and was
normalized to the endogenous reference control gene GAPDH.
Polysome analysis
Polysomes were isolated as described (Johannes and Sarnow,
1998). Brieﬂy, 20 million MCF7-vector control MCF7-treRNAs
were incubated with 100mg/ml cycloheximide for 3min at 37 1C
before harvesting and washed with ice-cold PBS containing 100 mg/
ml cycloheximide, lysed in 500 ml of polysome lysis buffer (15mM
Tris–HCl pH 7.4, 15mM MgCl2, 0.3M NaCl, 1mg/ml heparin,
0.1mg/ml cycloheximide, and 1% Triton X-100). Extracts were
incubated on ice for 10min and centrifuged at 13 000 r.p.m. for
10min at 4 1C to remove nuclei and debris. The supernatants were
layered on 10–50% continuous, linear sucrose gradients prepared
with lysis buffer without Triton X-100. The gradients were centri-
fuged in an SW41 Beckman rotor at 35 000 r.p.m. for 190min at 4 1C.
Gradients were collected into eleven 1ml fractions by monitoring
RNA absorbance at 254 nm using an ISCO fractionator (Brandel,
Inc.). RNA was extracted by precipitation with guanidinium-HCL
and ethanol followed by LiCl precipitation and further puriﬁed by
RNeasy column (Qiagen) according to the manufacturer’s instruc-
tions. RNA was treated with Turbo DNase (Ambion). RNA isolated
from the non-polysomal (fractions 1–6), LMW (fractions 7–8)
polysomal, and HMW polysomal (fractions 9–11) fractions was
pooled. In all, 0.5 mg of pooled RNA was reverse transcribed using
the Taqman reverse transcription kit (Applied Biosystems).
Resulting cDNA was subjected to qRT–PCR. The mRNA and
treRNA distribution across the polysome fractions was graphically
presented as the percentage. All polysomal analysis was done a
minimum of three times.
MS2 pull-down assay
MCF7 cells were infected with lentivirus expressing 30tagged
treRNA-MS2 or MS2 tag alone, and cells were harvested at 72 h
post infection. Cytoplasmic proteins were extracted using a NE-PER
Cytoplasmic and Nuclear Protein Extraction Kit (Thermo Scientiﬁc)
as per the manufacturer’s instructions and then incubated with
fusion MS2 binding protein-MBP bound amylose magnetic beads
for 3 h at 4 1C. The beads were subsequently washed thrice with
wash buffer 1 (20mM HEPES pH 7.9, 200mM KCl, and 1mM
EDTA); twice with wash buffer 2 (20mM HEPES pH 7.9, 20mM
KCl, and 1mM EDTA) and ﬁnally once with ice-cold PBS. Bound
proteins were dissociated by boiling with 1 SDS–PAGE sample
buffer and resolved on 15% SDS–PAGE. Samples were run 2 cm on a
1D SDS mini-gel, followed by staining with Colloidal Blue. The 2-cm
lanes were sliced into 10 uniform fractions, gel slices were destained
overnight, dried in a Speedvac, reduced using 100ml 20mM Tris(2-
carboxyethyl)phosphine hydrochloride (TCEP) in 25mM ammo-
nium bicarbonate, pH 8.0, and alkylated using 100ml 40mM iodoa-
cetamide in 25mM ammonium bicarbonate, pH 8.0. After thorough
washing, gel pieces were dried, rehydrated with 20ml of 0.02mg/ml
modiﬁed Trypsin (Promega) in 40mM ammonium bicarbonate, and
incubated overnight with shaking at 371C. The tryptic digest was
removed, gel slices were extracted with 20ml of 40mM ammonium
bicarbonate, supernatants were combined, and digestion was
stopped using 4 ml concentrated acetic acid. Tryptic digests were
analysed by injecting 5ml onto a 15-cm nanocapillary reverse-phase
column (New Objective PicoFrit 75mm column terminating in a
nanospray 15mm tip self-packed with Microm Magic C18 AQ 200A,
5mm resin), which was directly coupled to a ThermoElectron Orbitrap
XL mass spectrometer. Peptides were eluted at a ﬂow rate of 200nl/
min using 0.1% formic acid in MilliQ water as solvent A and 0.1%
formic acid in acetonitrile as solvent B and a gradient consisting of:
3–28% B over 40min, 28–50% over 25.5min, 50–80% B over 5min,
and a 4.5-min hold at 80% B before returning to initial conditions of
3% B. MS and MS/MS data were acquired in data-dependent mode
with full MS scans from m/z¼ 350–2000 at 60000 resolution using a
top six method with a minimum MS signal threshold of 1000.
RNA pull-down assay
To prepare a plasmid construct for the use as a template for RNA
synthesis, treRNAwas ampliﬁed by PCR and cloned into a pGEM-T
Easy (Promega) cloning vector. The constructs were linearized and
transcribed in vitro with biotin RNA labelling mix (Roche) and T7
RNA polymerase, treated with RNase-free DNase I (Roche), and
puriﬁed with the RNeasy Mini Kit (Qiagen). Biotinylated RNAs of
sense or antisense treRNA incubated with cytosolic extracts for 2 h
at 4 1C. Proteins bound were recovered by further incubating with
streptavidin magnetic beads for 1 h at 4 1C. The beads were washed
with binding and washing buffer (10mM Tris–HCl, 1mM EDTA, and
2m NaCl), boiled in SDS–PAGE sample buffer. Samples were
separated by SDS–PAGE and the retrieved proteins were detected
by the standard western blotting technique. To determine the
amount of E-cadherin, biotinylated treRNA or a vector control
was incubated with cytosolic cell extracts and pull-downs were
performed as described above. Total RNA was extracted from the
beads. One microgram of total RNA was transcribed and real-time
PCR was performed with gene-speciﬁc primers. Relative E-cadherin
mRNA level was normalized to GAPDH.
UV cross-linking IP assay
A549 cells (1107) were cultured in 150mm plates, washed with
PBS and UV cross-linked at 400mJ/cm2 in Stratalinker as described
(Ule et al, 2005). UV cross-linked or non-cross-linked cells were
lysed in RIPA buffer containing 1X protease inhibitor cocktail and
RNase inhibitor and incubated on ice for 10min. Protein G agarose
beads were washed with 1X IP buffer (50mM Tris, pH7.6, 100mM
NaCl, 0.5mM DTT, 2mMMgCl2, and 1X protease inhibitor cocktail)
and were coated with FXR1 antibody or FXR2 antibody or control
IgG. An aliquot (10%) of lysate was kept aside to use as an input
and the rest of the cell lysates was incubated with antibody or IgG-
coated beads at 4 1C overnight. The protein–RNA complexes on the
beads after IP were washed two times with 1X IP buffer and twice
with IP buffer containing 1M urea (Luo and Reed, 2003). RNA was
isolated from the beads and cDNA was synthesized with 0.5mg of
RNA as described above and used for real-time PCR analyses with
treRNA primer. The percent input was calculated using a Relative
Standard Curve Method.
IPs and immunoblotting
Cell pellets were lysed with lysis buffer (50mM Tris pH 7.4, 150mM
NaCl, 0.5% Triton X-100, 0.25% sodium deoxycholate, 1mM EGTA
pH 8.0, 50mM sodium ﬂuoride, 1mM sodium vanadate, and 10mM
sodium pyrophosphate with complete protease inhibitor; Roche). In
all, 200 mg of total cell lysate was incubated with primary antibody
and protein G or A sepharose beads (GE Healthcare) overnight
at 4 1C. The beads with bound proteins were pelleted and washed
six times with lysis buffer and once with ice-cold PBS. The beads
were boiled with 1X SDS–PAGE sample buffer. Five percent
input and ﬁfty percent of immunoprecipitated proteins were
separated using 4–12% SDS–PAGE gels and transferred onto
PVDF membrane (Millipore, Bedford, MA, USA). Membranes
were probed with speciﬁc primary antibodies. Blots were washed
and probed with respective secondary peroxidase-conjugated anti-
bodies, and the bands were visualized by chemoluminescence (GE
Healthcare). The following antibodies were used: rabbit polyclonal
E-cadherin, BUB3, hNRNP E1 (Cell Signaling Technology), mouse
monoclonal b catenin (BD Biosciences), rabbit polyclonal ZO-1
(Zymed Laboratories), mouse monoclonal eIF4G (Abcam), mouse
monoclonal Fibronectin and b-actin (Sigma-Aldrich), mouse mono-
clonal Vimentin (Calbiochem), rabbit polyclonal SF3B3, PUF60,
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hnRNP K, and TRIM25 (Bethyl Laboratories), mouse monoclonal
FXR1, FXR2 (Millipore), and secondary rabbit and mouse perox-
idase conjugated (GE Healthcare),
Luciferase reporter assay
The DNA fragments of 50UTR regions of human E-cadherin,
b-catenin and ZO1 were PCR ampliﬁed and cloned upstream of
the ﬁreﬂy luciferase gene in the pGL3 vector (Promega). 30UTR
regions of human E-cadherin, b-catenin, and ZO1 were PCR ampli-
ﬁed and cloned downstream of a ﬁreﬂy luciferase gene in pGL4
vector. Cells were co-transfected with 100 ng of treRNA, 0.5mg of
control or reporter DNA, and 0.2 ng of Renilla luciferase (pRL-TK) as
a normalizing control. Luciferase activity was determined using a
Dual-Luciferase Reporter Assay (Promega) according to the manu-
facturer’s instructions 48 h after transfections. Fireﬂy luciferase was
normalized against Renilla luciferase. Transfections were performed
in triplicates and repeated three times. Mutations in wild-type
human E-cadherin 3UTR were generated by replacing the three
potential binding sites with their respective reverse sequences
individually (site 1 from 12 to 80 bp; site 2 from 946 to 1019 bp;
site 3 from 1325 to 1396 bp downstream of stop codon), and
performed the luciferase assay as described above.
Isolation of nuclear and cytoplasmic RNAs
Nuclear and cytoplasmic RNAs were isolated from A549 cell line,
with a Norgen Biotek Corp Cytoplasmic and Nuclear RNA
Puriﬁcation Kit (Cat # 2100) according to the manufacturer’s
instructions. To remove genomic DNA contamination, on-column
DNase digestion reaction was performed. First-strand cDNA was
synthesized from 2.0mg of cytoplasmic and nuclear RNAs using a
Superscript First-Strand Synthesis System kit (Invitrogen). PCRs
were performed with the following primer combinations: treRNA
(F-50-AATGAAAACACCAGGCCGGG-30 and R-50-TCTCACTCTCTCAA
ATCGGC-30) Nuclear-speciﬁc gene U2 snRNA (F-50-CATCGCTTCTC
GGCCTTTTG-30 and R-50-TGGAGGTACTGCAATACCAGG-30) and
cytoplasm-speciﬁc gene S14 (F-50-GGCAGACCGAGATGAATCCTC-30
and R-50-CAGGTCCAGGGGTCTTGGTCC-30). The experiment was
repeated three times and each sample measured as duplicates.
Statistical analysis
For treRNA expression in breast cancer, two samples were collected
from each patient. One sample was from the primary tumour, and
the other was from metastasis. The experiments were performed
twice for each sample. To assess the reproducibility of quantitative
measurements of the studied gene expression, intraclass correlation
coefﬁcients (ICCs) were calculated and results show a high degree
of consistency between two experiments for both tumour samples
(ICC¼ 99% with standard error, s.e.¼ 0.005) and metastasis sam-
ples (ICC¼ 96% with s.e.¼ 0.021). To examine whether the level of
gene expression in metastasis is different from that in primary
tumours, the average of gene expression from the replicates of
each sample was calculated and then log-transformed for statistical
comparison using a paired t-test. The difference in the log-trans-
formed gene expression levels between paired metastasis and
primary tumour is equivalent to the log-transformed ratio of gene
expression levels in metastasis versus that in primary tumour. For
the treRNA expression in colon cancer samples (n¼ 56) and normal
colon tissues (n¼ 19), log-transformed treRNA data were used for
two-group t-test. Stata 12.0 (StataCorp LP, College Station, TX, USA)
was used for data analysis.
GenBank accession number:
The GenBank accession numbers are FXR1: NM_005087, FXR2:
NM_004860, hnRNP K: NM_002140, PUF60: NM_078480, SF3B3:
NM_012426, BUB3: NM_004725, andTRIM25: NM_005082.
ShRNA sequences
The shRNA sequences are FXR1shRNA1 CCGGGCTAAAGTTCGGAT
GATGAAACTCGAGTTTCATCATCCGAACTTTAGCTTTTTTG; FXR1
shRNA2: CCGGGCTAGAGGTTTCTTGGAATTTCTCGAGAAATTCCA
AGAAACCTCTAGCTTTTTTG; FXR2 shRNA1: CCGGGCGGATGATG
AAGGGAGATTTCTCGAGAAATCTCCCTTCATCATCCGCTTTTT; FXR2
shRNA2: CCGGCGAGATACAATTCTTCATCTACTCGAGTAGATGAAG






TTTTT; hnRNP KshRNA1: CCGGGCCAGTGTTTCAGTCCCAGACCTC
GAGGTCTGGGACTGAAACACTGGCTTTTTG; hnRNP KshRNA2:
CCGGTGATGTTTGATGACCGTCGCGCTCGAGCGCGACGGTCATCAAA









GGCACTTTTT; and control shRNA: CCGGCAACAAGATGAAGAGCA
CCAACTCGAGTTGGTGCTCTTCATCTTGTTGTTTTT.
Primer sequences for the construction of 3 0UTR and 50UTR
reporter plasmids
The primer sequences are E-cadherin 30UTR Forward (50-30)
GGGACTCGAGAGAGGCGGGC; E-cadherin 30UTR Reverse (50-30)
ATGGTTTAACAAAATTGTTTAATAAAATTTATAAAAAT; ZO1 30UTR
Forward (50-30) CTCTTGAA ATATAGGAAC TTAAATAATGTGAA; ZO1
30UTR Reverse (50-30) TTTATTTTAAAAAGTTTTATTTTGGAGATTTA
GAA; Bcatenin 30UTR Forward (50-30) ATCATC CTTTAGGTAA GA
AGTTTTAA AAAGC; Bcatenin 30UTR Reverse (50-30) CAATCGAA
TGAATTAAAAGTTTAATTCTGAAC; E-cadherin 50UTR Forward
(50-30) AGCCAATCAGCGGTACGGGGG; E-cadherin 50UTR Reverse
(50-30) GGCTGGCCGGGGACGCCG; Bcatenin 50UTR Forward (50-30)
AGGATACAGC GGCTTCTGCGCG; Bcatenin 50UTR Reverse (50-30)
TGTCCACGCTGGATTTTCAAAACAG; ZO1 50UTR Forward (50-30) CG
GGCATGCT CAGTGGGC; and ZO1 50UTR Reverse (50-30) CTTGTCTC
TCTCCAGCGCCG.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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